Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bisphosphonate therapy for postmenopausal osteoporosis.

N B Watts1

  • 1Section of Internal Medicine, Emory Clinic, Atlanta, Ga.

Southern Medical Journal
|August 1, 1992
PubMed
Summary

Bisphosphonates are antiresorptive drugs that increase bone mass, offering potential osteoporosis treatment. Intermittent etidronate therapy effectively addresses postmenopausal osteoporosis, with newer bisphosphonates in clinical trials.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The effects of spaceflight countermeasures on trabecular bone score (TBS) of the lumbar spine.

Archives of osteoporosis·2026
Same author

Forearm bone mineral density and fracture incidence in postmenopausal women with osteoporosis: results from the ACTIVExtend phase 3 trial.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2020
Same author

Correction to: Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2020
Same author

Correction to: Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2020
Same author

Factors associated with the contemplative stage of readiness to initiate osteoporosis treatment.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2020
Same author

Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2019

Area of Science:

  • Pharmacology
  • Bone Biology
  • Endocrinology

Background:

  • Osteoporosis is a significant health concern, characterized by reduced bone mass and increased fracture risk.
  • Bisphosphonates are a class of drugs known for their antiresorptive properties, crucial for managing bone density disorders.
  • Understanding the mechanism of action of bisphosphonates is key to developing effective osteoporosis therapies.

Purpose of the Study:

  • To evaluate the efficacy of bisphosphonates as a treatment for osteoporosis.
  • To investigate the antiresorptive mechanisms of bisphosphonates, focusing on osteoclast activity.
  • To review the clinical effectiveness of intermittent cyclical therapy with etidronate for postmenopausal osteoporosis.

Main Methods:

  • Review of existing clinical studies on bisphosphonate therapy for osteoporosis.

Related Experiment Videos

  • Analysis of the effects of bisphosphonates on osteoclast activation and bone resorption.
  • Examination of data from controlled studies evaluating intermittent etidronate therapy.

    • Main Results:

    • Bisphosphonates increase bone mass by inhibiting osteoclast activity, either by reducing activation frequency or resorption depth.
    • Intermittent cyclical therapy with etidronate demonstrated efficacy in two controlled studies for postmenopausal osteoporosis.
    • Ongoing clinical trials are investigating the potential of second- and third-generation bisphosphonates.

    Conclusions:

    • Bisphosphonates represent a promising therapeutic strategy for osteoporosis management.
    • Etidronate, administered via intermittent cyclical therapy, is an effective treatment for postmenopausal osteoporosis.
    • Further research and clinical trials are advancing the development of novel bisphosphonate agents.